Retrospective Cohort Study
Copyright ©The Author(s) 2023.
World J Transplant. Jun 18, 2023; 13(4): 138-146
Published online Jun 18, 2023. doi: 10.5500/wjt.v13.i4.138
Table 1 Differences in demographics, transplant risk, reflux parameters, and post-transplant management between cystic fibrosis subjects receiving and not receiving pre-transplant gastroesophageal reflux evaluation, n (%)
Covariate
CF patients with pre-transplant reflux testing (n = 41)
CF patients without pre-transplant reflux testing (n = 19)
P value
Male gender21 (51.2)9 (47.4)1.00
Age at lung transplant35.8 ± 8.2130.1 ± 7.890.01
Body mass index20.4 ± 2.5119.4 ± 1.970.11
Caucasian race41 (100)19 (100)1.00
FEV1 before transplant0.84 ± 0.36)0.75 ± 0.220.24
LVEF before transplant0.60 ± 0.050.59 ± 0.050.52
Bilateral lung transplant41 (100)19 (100)1.00
CMV mismatch15 (36.6)6 (31.6)0.78
High-risk donor001.00
GER symptoms before transplant22 (53.7)5 (26.3)0.06
Pre-transplant PPI use27 (65.8)16 (84.2)0.22
Abnormal testing/Acid reflux24 (58.4)-
Post-transplant PPI use34 (82.9)17 (89.5)0.70
Post-transplant Nissen fundoplication8 (19.5)0 (0)0.05
Any infection35 (85.4)17 (89.5)1.00
Acute rejection12 (29.3)7 (36.8)0.56
Chronic rejection/CLAD9 (21.9)12 (63.1)0.02
Death (All-cause)8 (19.5)8 (42.1)0.11
Death (Pulmonary)5 (12.2)6 (31.6)0.09
Table 2 Cox multivariate time-to-event analysis demonstrating the association between pre-transplant reflux testing and reduction in chronic rejection (chronic lung allograft dysfunction) in cystic fibrosis patients, after controlling for confounders, suggesting that reflux testing and timely treatment may reduce rejection in this patient cohort
Covariate
Cox multivariate analysis hazard ratios for chronic lung allograft dysfunction
P
Pre-transplant reflux testing0.26 (0.08-0.92)0.03
Gastroesophageal reflux symptoms before transplant3.13 (1.03-9.54)0.04
Forced expiratory volume in 1 second before transplant3.17 (0.61-16.4)0.17
Body mass index0.98 (0.75-1.28)0.88
Age at transplant0.98 (0.90-1.05)0.54